(15352506), C. A., (15352509), A. B., (15352512), R. S., (15352515), M. G., (15352518), A. C., (15086287), D. R., . . . (15352566), C. C. (2025). Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Citazione stile Chigago Style (17a edizione)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.
Citatione MLA (9a ed.)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.